SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp move is drawing attention after Morgan Stanley named it a top pick, citing accelerating AWS growth and AI opportunities; traders are also pointing to Amazons Trainium software announcement as a potential boost to cloud-chip adoption. The reaction is broadly bullish, though some remain cautious about heavy AI capital spending and whether the gains will hold.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reports of Lundbecks interest in acquiring Xeris have fueled heavy-volume trading and takeover speculation, though the company has said it is not for sale and no deal is confirmed. Traders are split between expecting further buyer interest and viewing the chatter as unsubstantiated, while some point to Recorlev growth and XP-8121s pipeline potential as standalone reasons for optimism.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are debating whether the move can continue, with some citing short-squeeze potential and others warning of profit-taking, safety concerns around dizziness, and the fact that FDA approval is still pending.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Recent open-market purchases by Celsius executives and directors have fueled bullish discussion around the shares, while skeptics question whether the buys signal durable confidence given concerns about the core brands sales and management execution. Traders also revive speculation about a Pepsi buyout, but no deal is confirmed.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Anticipation of Vicors Q3 earnings is driving discussion after the company raised its sequential growth outlook twice, with traders pointing to higher royalties from its Vertical Power Delivery licensing. Bulls expect the stronger outlook to show up in results, while others are wary of the sharp pullback and volatility despite the guidance increases.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix shares are under pressure as EyePoints failed wet-AMD trial has heightened doubts about TKI-based treatments, prompting traders to question whether those concerns could extend to Oculars AXPAXLI program. Some investors view the selloff as spillover from a competitors results, while others cite clinical uncertainty and the departure of Oculars chief strategy officer as additional concerns.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-cleared expansion of Alpha Taus REGAIN trial in recurrent glioblastoma is a key focus, alongside planned trial data at SNO 2026. Traders are optimistic about early local-control results, while some note that they come from a small initial cohort; the completed enrollment of the pancreatic IMPACT study is another pipeline catalyst discussed.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-guided Q3 report and an upbeat 2027 EBITDA outlook are driving CLFs rally. Bulls see improving steel prices and earnings potential, while skeptics warn that debt and the reliance on favorable price forecasts could limit the recovery; traders are also debating whether the move will hold or fade as a sell-the-news rally.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO decline dominates discussion, with traders pointing to insider selling and upcoming share unlocks alongside concerns about valuation, scaling and reliance on OpenAI amid weakness across AI stocks. Some see the selloff as an oversold buying opportunity and are averaging in, while others expect further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ rebounded as technology and AI stocks recovered from a sharp selloff, with traders debating whether the move marks a durable recovery or a low-volume bull trap. Upcoming megacap earnings and AI spending plans are a key focus for the tech-heavy index.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NKE Stock Wrapped Its Best Week In 3 Months: Analyst Says Nike Will Recover From ‘Lackluster Product Development,’ Shares Undervalued 

Equity

Morningstar expects innovation, marketing, retail partnerships, and $2.5 billion in cost savings to support a long-term recovery. 


VSXY Stock Rises Overnight: Victoria’s Secret Taps Kylie Jenner’s Star Power To Spruce Up Fashion Show Buzz 

Victoria’s Secret returned to Los Angeles with a star-studded fashion show.


LULU Stock Heads For Second Week Of Decline: Lululemon Overhauls Leadership To Reignite Growth 

New product and operations leaders aim to boost Lululemon’s innovation and strengthen its connection with customers. 


‘The Big Short’ Investor Michael Burry Justifies Lululemon Tax-Loss Sale: ‘I Am Not Throwing In The Towel’ 

Michael Burry sold Lululemon to harvest tax losses and bought Deckers as a temporary proxy. 


NKE Stock Heads For Its Worst Year Ever: Nike’s 45% Plunge Tests Investor Patience As China And Core Brands Weaken

Nike’s weak China sales, struggling brands, and analyst downgrades are raising doubts about the company’s turnaround. 

NKE Stock Heads For A Weekly Loss: Morningstar Says Nike's Fresh Cost Cuts Signal A Longer Road To Recovery 

Nike stock slides as Morningstar flags a prolonged turnaround, citing weak sales, Greater China challenges, and restructuring costs.


NKE Stock Ticks Higher Overnight: Retail Stays Bullish On Nike Ahead of Q1 Earnings – 'Time To Reinvest' 

Nike faces a major earnings test as shares plunge 44% year-to-date, and short interest reaches 87 million shares. 


NKE Ticks Higher Ahead Of Q1 As Short Interest Hits Record 87M Shares — Could Earnings Squeeze The Bears?

Short sellers are sitting on an estimated $1.4 billion in paper gains this year, but a better-than-expected report could force some to cover, according to S3 Partners.

NKE Stock Heads For Another Month In The Red: Jefferies Bets On Nike's Recovery, Sees A Q1 Earnings Beat 

Jefferies sees November’s investor day supporting Nike’s turnaround. 


GAP Stock Heads For Monthly Loss Despite CEO Optimism On Old Navy — Cardi B Campaign Fails To Lift Retail Mood

Gap CEO Richard Dickson said Old Navy has diagnosed seasonal product issues and improved its assortment and marketing. 


Corgi ETF Trust I. - Corgi Lifestyle Brands ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Morningstar lowered Nike’s competitive advantage rating as rivals like Hoka and On gain ground.&nbsp;</li><li>Nike’s U.S. footwear market share dropped to 30% as retailer relationships weakened, but its strong brand keeps the stock undervalued.&nbsp;</li><li>Under CEO Elliott Hill, Nike plans to save $2.5 billion through job cuts and restructuring.</li></ul><p>Nike Inc. (NKE) stock wrapped up its best week in three months, with Morningstar saying the sportswear giant’s shares remain undervalued despite mounting competition and a weaker outlook. The analyst cut Nike’s fair value estimate but expects innovation, stronger marketing and improved retail partnerships to support a recovery.&nbsp;</p><p><a href="https://stocktwits.com/symbol/NKE">Nike stock</a> edged 0.05% lower in Monday’s premarket</p><h2 class="st-heading-2">Competition Weakens Nike’s Edge</h2><p>Morningstar analyst David Swartz reduced Nike’s economic moat rating to ‘narrow’ from ‘wide.’ The analyst believes Nike retains a powerful brand, premium pricing, and valuable relationships across professional sports. Swartz also added that Nike stock is still undervalued. However, newer rivals, including Deckers Brands (DECK) through its Hoka brand and On Holding AG (ONON), have intensified pressure on Nike’s lead in performance footwear.</p><p>Nike’s share of the U.S. sports shoe market dropped to 30% in 2025 from 40% in 2016. Morningstar said Nike’s focus on direct sales hurt relationships with retailers and caused the brand to lose some loyal customers. The analyst sees Nike as a leader in sportswear and expects it to recover from problems including “lackluster product development, soft sportswear demand, and strained relationships with wholesale accounts.”</p><h2 class="st-heading-2">Nike’s Fiscal 2027 Outlook Remains Challenging</h2><p>Morningstar expects Nike’s sales to decline 8% in fiscal 2027, compared with its previous forecast of a 2% decline. The analyst also lowered the operating margin outlook to 5.9% from 6.8% and slashed the earnings-per-share estimate to $1.16 from $1.69.</p><p>The firm now sees annual sales growth of 3% over the coming decade, down from 5%. Its peak operating margin forecast fell to 14% from 18%, reflecting mounting competition and slower growth in key markets, specifically China.</p><h2 class="st-heading-2">Innovation And Cost Cuts Drive Nike’s Turnaround Plans</h2><p>Under CEO Elliott Hill, Nike is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nke-stock-slumps-about-9-after-hours-on-a-soft-full-year-forecast-ceo-says-the-fix-will-take-time/cZD0ZX3RB0j">working</a> to strengthen retailer relationships, improve product development and reconnect with athletes and sports communities worldwide. The company is also pursuing a restructuring program designed to bring in $2.5 billion in savings over four years through job cuts and fewer management layers.</p><p>Morningstar expects Nike to redirect some of those savings toward technical development, marketing and a more responsive supply chain. The analyst believes these investments could help restore sales momentum and lift operating margins toward 14% over the next decade.</p><h2 class="st-heading-2">China And Consumer Demand Pose Risks For Nike&nbsp;</h2><p>Nike’s recovery in China remains uncertain as domestic competitors gain ground and consumer traffic weakens. Morningstar reduced its forecast for the region’s annual sales growth over the next decade to 1% from 9% previously. Tariffs, higher energy costs and inflation also threaten profit and consumer spending.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/fiscal_ai_chart_export_21_2fd96e684b.png" alt="fiscal-ai-chart-export (21).png" width="1400" height="1000"></figure><p>Despite the challenges, Morningstar expects Nike’s strong brand to help it earn returns above its 9% capital cost. The analyst also expects Nike to maintain a dividend yield above 4%, although weak results may limit buybacks.&nbsp;</p><h2 class="st-heading-2">NKE stock: Retail View&nbsp;</h2><p>On Stocktwits, retail sentiment around the stock slipped to ‘bearish’ from ‘neutral’.</p><p>NKE stock has crashed over 41% year-to-date.&nbsp;</p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stocktwits-retail-therapy-staples-defy-market-rout-in-best-week-since-february-cracker-barrel-signet-and-vf-steal-the-show/cZx8i3jRBMB">Stocktwits Retail Therapy: Staples Defy Market Rout In Best Week Since February — Cracker Barrel, Signet And VF Steal The Show</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Nike shoes are displayed at a shoe store in Novato, California. 

Nike Inc. (NKE) stock wrapped up its best week in three months, with Morningstar saying the sportswear giant’s shares remain undervalued despite mounting competition and a weaker outlook. The analyst cut Nike’s fair value estimate but expects innovation, 

NKE Stock Wrapped Its Best Week In 3 Months: Analyst Says Nike Will Recover From ‘Lackluster Product Development,’ Shares Undervalued

Deckers Outdoor Corp.

Nike Inc

On Holding AG

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Feed

News

Sentiment

Fundamentals

Info

STYL News